Polynovo (ASX:PNV) Cash And Cash Equivalents : A$45.58 Mil (As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

What is Polynovo Cash And Cash Equivalents?

Polynovo's quarterly cash and cash equivalents declined from Dec. 2022 (A$50.48 Mil) to Jun. 2023 (A$46.85 Mil) but then stayed the same from Jun. 2023 (A$46.85 Mil) to Dec. 2023 (A$45.58 Mil).

Polynovo's annual cash and cash equivalents declined from Jun. 2021 (A$7.69 Mil) to Jun. 2022 (A$6.10 Mil) but then increased from Jun. 2022 (A$6.10 Mil) to Jun. 2023 (A$46.85 Mil).

Polynovo Cash And Cash Equivalents Historical Data

The historical data trend for Polynovo's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Polynovo Cash And Cash Equivalents Chart

Polynovo Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash And Cash Equivalents

Get a 7-Day Free Trial

13.92

11.65

7.69

6.10

46.85

Polynovo Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															3.29	6.10	50.48	46.85	45.58

Polynovo Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Polynovo (ASX:PNV) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Polynovo Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Polynovo's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Polynovo (ASX:PNV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Polynovo Ltd (ASX:PNV) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

CALZF:USA MFJ:Germany

Address

320 Lorimer Street, Unit 2, Port Melbourne, VIC, AUS, 3207

Website

https://www.polynovo.com

Polynovo earns most of its revenue from U.S. sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.

Polynovo (ASX:PNV) Headlines

No Headlines